Regenxbio (RGNX) Misses Q4 EPS by 14c

Regenxbio (NASDAQ: RGNX) reported Q4 EPS of ($1.38), $0.14 worse than the analyst estimate of ($1.24). Revenue for the quarter came in at $31.35 million versus the consensus estimate of $39.41 million.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
• Danone SA (BN:FP) (DANOY) PT Raised to EUR63 at Deutsche Bank